CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 886 enrolled
Drug / intervention
Levocetirizine +1 moredrug
Likely dose
Levocetirizine 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00264303
NCT00264303Phase 4Completed

A Comparative Study on Clinical Efficacy and Safety of Levocetirizine 5 mg Oral Capsules Once Daily in the Morning vs. Desloratadine 5 mg Oral Capsules Once Daily in the Morning in Patients Suffering From Chronic Idiopathic Urticaria (CIU)

UCB Pharma·interventional·Posted Dec 12, 2005·Updated Aug 31, 2011

In Brief

A Phase 4 clinical trial evaluating Levocetirizine and Desloratadine for Chronic Idiopathic Urticaria. Completed, enrolled 886 participants across 80 sites in 9 countries.

Detailed Summary

A study to compare the clinical efficacy and safety of Levocetirizine vs. Desloratadine in patients suffering from Chronic Idiopathic Urticaria (CIU) measured by the mean pruritus severity score over the first week of treatment

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, France, Germany, Italy, Malaysia, Romania, South Africa, Spain, United Kingdom
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 12, 2005
Enrollment StartDec 1, 2005
Primary CompletionJan 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 20.6 years ago

Interventions

Levocetirizinedrug

5mg oral capsules, once daily, 4 week duration

Desloratadinedrug

5mg oral capsules, once daily, 4 week duration